Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Sirona Biochem Corp.    SBM   CA82967M1005

SIRONA BIOCHEM CORP.

(SBM)
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Sirona Biochem : Announces Change of Auditor

share with twitter share with LinkedIn share with facebook
share via e-mail
02/14/2020 | 07:01pm EST

VANCOUVER, Feb. 14, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the "Company") announces that it has changed its auditors from MNP LLP (the "Former Auditor") to DeVisser Gray LLP (the "Successor Auditor") effective January 27, 2020 and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective January 27, 2020 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor's audit reports for the relevant period, being the financial years ended October 31, 2018 and October 31, 2017 and any period subsequent to the most recently completed financial year for which an audit report was issued and preceding the resignation of the Former Auditor. In accordance with National Instrument 51-102 – Continuous Disclosure Obligations ("NI 51-102"), the Company has filed a Change of Auditor Notice (the "Notice") on SEDAR together with letters from both the Former Auditor and Successor Auditor, with each lettering confirming agreement with the statements contained in the Notice, as applicable.  There were no reportable events as defined in NI 51-102 between the Former Auditor and the Company.

Sirona Biochem Corp. (CNW Group/Sirona Biochem Corp.)

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona's subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.

For more information, please visit www.sironabiochem.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

© Canada Newswire, source Canada Newswire English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SIRONA BIOCHEM CORP.
02/14SIRONA BIOCHEM : Announces Change of Auditor
AQ
01/23SIRONA BIOCHEM : 100% Safety in Final Tox Study for Increased Concentration of T..
AQ
01/22/R E P E A T -- SIRONA BIOCHEM : 100% Safety in Final Tox Study for Increased Co..
AQ
01/22SIRONA BIOCHEM : 100% Safety in Final Tox Study for Increased Concentration of T..
AQ
01/21SIRONA BIOCHEM : Announces Grant of Stock Options
AQ
2019SIRONA BIOCHEM : R E P E A T -- Sirona Biochem CEO Letter to Shareholders/
AQ
2019SIRONA BIOCHEM : CEO Letter to Shareholders
AQ
2019SIRONA BIOCHEM : R E P E A T -- Sirona Biochem Reports 100% Safety in First Tox ..
AQ
2019SIRONA BIOCHEM : Reports 100% Safety in First Tox Study for Increased Concentrat..
AQ
2019SIRONA BIOCHEM : R E P E A T -- Sirona Biochem Proceeds to First Clinical Tests ..
AQ
More news
Chart SIRONA BIOCHEM CORP.
Duration : Period :
Sirona Biochem Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Howard Jarman Verrico Chairman, Chief Executive Officer & Secretary
Michelle Seltenrich Vice President-Operations
Christopher D. Hopton Chief Financial Officer & Director
Géraldine Deliencourt-Godefroy Director & Chief Scientific Officer
Alex Sandro Marazzi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SIRONA BIOCHEM CORP.-29.55%52
LONZA GROUP12.66%30 442
IQVIA HOLDINGS INC.-7.62%27 523
CELLTRION, INC.-1.73%18 820
SEATTLE GENETICS, INC.-5.21%18 657
INCYTE CORPORATION-10.71%16 440